Global Chronic Lymphocytic Leukemia Therapeutics Market

  1. Global Chronic Lymphocytic Leukemia Therapeutics Market Methodology and Scope

    1. Research Methodology

    2. Research Objective and Scope of the Report

  2. Global Chronic Lymphocytic Leukemia Therapeutics Market – Market Definition and Overview

  3. Global Chronic Lymphocytic Leukemia Therapeutics Market – Executive Summary

    1. Market Snippet by Cancer Type

    2. Market Snippet by Drug Type

    3. Market Snippet by Route of Administration

    4. Market Snippet by Region

  4. Global Chronic Lymphocytic Leukemia Therapeutics Market – Market Dynamics

    1. Market Impacting Factors

      1. Drivers

        1. High Prevalence of CLL(Chronic Lymphocytic Leukemia)

        2. Technological Advancements

      2. Restraints

        1. High Cost of Treatment

      3. Opportunity

      4. Impact Analysis

  5. Global Chronic Lymphocytic Leukemia Therapeutics Market – Industry Analysis

    1. Porter's Five Forces Analysis

    2. Regulatory Analysis

    3. Patent Analysis

  6. Global Chronic Lymphocytic Leukemia Therapeutics Market – Epidemiology Analysis

  7. Global Chronic Lymphocytic Leukemia Therapeutics Market – Pipeline Analysis

    1. Pipeline Overview

    2. Key Pipeline Product Profiles

  8. Global Chronic Lymphocytic Leukemia Therapeutics Market – By Cancer Type

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

      2. Market Attractiveness Index, By Cancer Type

    2. B-cell chronic lymphocytic leukemia

      1. Introduction

      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

    3. T-cell chronic lymphocytic leukemia

    4. Natural killer chronic lymphocytic leukemia.

  9. Global Chronic Lymphocytic Leukemia Therapeutics Market – By Drug Type

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

      2. Market Attractiveness Index, By Drug Type

    2. Chemotherapy Drugs

      1. Introduction

      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

    3. Immuno and Targeted Drugs

      1. Venetoclax

      2. Ibrutinib

      3. Obinutuzumab

      4. Duvelisib

      5. Others

  10. Global Chronic Lymphocytic Leukemia Therapeutics Market – By Route of Administration

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

      2. Market Attractiveness Index, By Route of Administration

    2. Intravenous route

      1. Introduction

      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

    3. Oral Route

    4. Others

  11. Global Chronic Lymphocytic Leukemia Therapeutics Market – By Region

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

      2. Market Attractiveness Index, By Region

    2. North America

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. The U.S.

        2. Canada

        3. Mexico

    3. Europe

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. Germany

        2. The U.K.

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

    4. South America

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. Brazil

        2. Argentina

        3. Rest of South America

    5. Asia Pacific

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. China

        2. India

        3. Japan

        4. Australia

        5. Rest of Asia Pacific

    6. Middle East & Africa

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

  12. Global Chronic Lymphocytic Leukemia Therapeutics Market – Competitive Landscape

    1. Competitive Scenario

    2. Competitor Chronic Lymphocytic Leukemia Therapeutics Strategy Analysis

    3. Comparative Product Portfolio Analysis

    4. Market Positioning/Share Analysis

    5. Mergers and Acquisitions Analysis

  13. Global Chronic Lymphocytic Leukemia Therapeutics Market - Company Profiles

    1. GlaxoSmithKline Plc

      1. Company Overview

      2. Product Portfolio and Description

      3. Key Highlights

      4. Financial Overview

    2. AbbVie Inc.

    3. Biogen Idec

    4. AstraZeneca

    5. Genentech Inc.

    6. MorphoSys AG

    7. F. Hoffmann-La Roche AG

    8. Teva Pharmaceutical Industries Ltd.

    9. Portola Pharmaceuticals, Inc

    10. Celgene Corporation

  14. Global Chronic Lymphocytic Leukemia Therapeutics Market – Premium Insights

  15. Global Chronic Lymphocytic Leukemia Therapeutics Market – DataM

    1. Appendix

    2. About Us and Services

    3. Contact Us

 

Guide this sample report to your Inbox

Please fill in all the fields below.

Note: Your privacy is important to us. Any information you provide to us is stored on our secure servers.

LIST OF TABLES

TABLE 01.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE, 2018, 2022 & 2026, BY CANCER TYPE, ($MILLION)

TABLE 02.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE 2018, 2022 & 2026, BY ROUTE OF ADMINISTRATION, ($MILLION)

TABLE 03.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE 2018, 2022 & 2026, BY DRUG TYPE, ($MILLION)

TABLE 04.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE 2018, 2022 & 2026, BY REGION, ($MILLION)

TABLE 05.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE 2018, 2022 & 2026 (%), BY CANCER TYPE ($MILLION)

TABLE 06.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY CANCER TYPE, 2018–2026 ($MILLION)

TABLE 07.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE 2018, 2022 & 2026 (%), BY ROUTE OF ADMINISTRATION ($MILLION)

TABLE 08.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY APPICATION, 2018–2026 ($MILLION)

TABLE 09.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE 2018, 2022 & 2026 (%), BY DRUG TYPE ($MILLION)

TABLE 10.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY DRUG TYPE, 2018–2026 ($MILLION)

TABLE 11.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE 2018, 2022 & 2026 (%), BY REGION ($MILLION)

TABLE 12.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY REGION, 2018–2026 ($MILLION)

TABLE 13.    NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY CANCER TYPE, 2018–2026 ($MILLION)

TABLE 14.    NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

TABLE 15.    NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY DRUG TYPE, 2018–2026 ($MILLION)

TABLE 16.    NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY COUNTRY, 2018–2026 ($MILLION)

TABLE 17.    SOUTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY CANCER TYPE, 2018–2026 ($MILLION)

TABLE 18.    SOUTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

TABLE 19.    SOUTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY DRUG TYPE, 2018–2026 ($MILLION)

TABLE 20.    SOUTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY COUNTRY, 2018–2026 ($MILLION)

TABLE 21.    EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY CANCER TYPE, 2018–2026 ($MILLION)

TABLE 22.    EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

TABLE 23.    EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY DRUG TYPE, 2018–2026 ($MILLION)

TABLE 24.    EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY COUNTRY, 2018–2026 ($MILLION)

TABLE 25.    ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY CANCER TYPE, 2018–2026 ($MILLION)

TABLE 26.    ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

TABLE 27.    ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY DRUG TYPE, 2018–2026 ($MILLION)

TABLE 28.    ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY COUNTRY, 2018–2026 ($MILLION)

TABLE 29.    MIDDLE EAST & AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY CANCER TYPE, 2018–2026 ($MILLION)

TABLE 30.    MIDDLE EAST & AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

TABLE 31.    MIDDLE EAST & AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY DRUG TYPE, 2018–2026 ($MILLION)

TABLE 32.    GLAXOSMITHKLINE PLC: OVERVIEW

TABLE 33.    GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 34.    GLAXOSMITHKLINE PLC: KEY DEVELOPMENTS

TABLE 35.    ABBVIE INC: OVERVIEW

TABLE 36.    ABBVIE INC: PRODUCT PORTFOLIO

TABLE 37.    ABBVIE INC: KEY DEVELOPMENTS

TABLE 38.    BIOGEN IDEC: OVERVIEW

TABLE 39.    BIOGEN IDEC: PRODUCT PORTFOLIO

TABLE 40.    BIOGEN IDEC: KEY DEVELOPMENTS

TABLE 41.    ASTRAZENECA: OVERVIEW

TABLE 42.    ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 43.    ASTRAZENECA: KEY DEVELOPMENTS

TABLE 44.    GENENTECH INC: OVERVIEW

TABLE 45.    GENENTECH INC: PRODUCT PORTFOLIO

TABLE 46.    GENENTECH INC: KEY DEVELOPMENTS

TABLE 47.    MORPHOSYS AG: OVERVIEW

TABLE 48.    MORPHOSYS AG: PRODUCT PORTFOLIO

TABLE 49.    MORPHOSYS AG: KEY DEVELOPMENTS

TABLE 50.    F. HOFFMANN-LA ROCHE AG.: OVERVIEW

TABLE 51.    F. HOFFMANN-LA ROCHE AG.: PRODUCT PORTFOLIO

TABLE 52.    F. HOFFMANN-LA ROCHE AG.: KG: KEY DEVELOPMENTS

TABLE 53.    TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW

TABLE 54.   TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTPORTFOLIO

TABLE 55.    TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS

TABLE 56.    PORTOLA PHARMACEUTICALS, INC: OVERVIEW

TABLE 57.    PORTOLA PHARMACEUTICALS, INC: PRODUCT PORTFOLIO

TABLE 58.    PORTOLA PHARMACEUTICALS, INC: KEY DEVELOPMENTS

TABLE 59.    CELGENE CORPORATION: OVERVIEW

TABLE 60.    CELGENE CORPORATION: PRODUCT PORTFOLIO

TABLE 61.    CELGENE CORPORATION: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE, 2018 & 2026 (%), BY CANCER TYPE

FIGURE 02.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE, 2018 & 2026 (%), BY ROUTE OF ADMINISTRATION

FIGURE 03.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE, 2018 & 2026 (%), BY DRUG TYPE

FIGURE 04.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE, 2018 & 2026 (%), BY REGION

FIGURE 05.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE, 2018 - 2026 AND YEAR ON YEAR GROWTH

FIGURE 06.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2026 (%), BY CANCER TYPE

FIGURE 07     GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA, 2018–2026 ($MILLION)

FIGURE 08     GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY T-CELL CHRONIC LYMPHOCYTIC LEUKEMIA, 2018–2026 ($MILLION)

FIGURE 09     GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY NATURAL KILLER CHRONIC LYMPHOCYTIC LEUKEMIA, 2018–2026 ($MILLION)

FIGURE 10.    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2026 (%), BY ROUTE OF ADMINISTRATION

FIGURE 11     GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE, BY INTRAVENOUS ROUTE, 2018–2026 ($MILLION)

FIGURE 12    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE, BY ORAL ROUTE, 2018–2026 ($MILLION)

FIGURE 13     GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE, BY SUBCUTANEOUS ROUTE, 2018–2026 ($MILLION)

FIGURE 14    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE, BY INTRATHECAL ROUTE, 2018–2026 ($MILLION)

FIGURE 15     GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE, BY INTRAMUSCULAR ROUTE, 2018–2026 ($MILLION)

FIGURE 16   GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2026 (%), BY DRUG TYPE

FIGURE 17     GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY Chemotherapy Drugs, 2018–2026 ($MILLION)

FIGURE 18     GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY Targeted Drugs, 2018–2026 ($MILLION)

FIGURE 19    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , BY OTHERS, 2018–2026 ($MILLION)

FIGURE 20    GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2026 (%), BY REGION

FIGURE 21 NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , 2018–2026 ($MILLION)

FIGURE 22     NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY PRODUCT CANCER TYPE, 2018–2026 ($MILLION)

FIGURE 23     NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

FIGURE 24     NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY DRUG TYPE, 2018–2026 ($MILLION)

FIGURE 25     NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018–2026 ($MILLION)

FIGURE 26    SOUTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , 2018–2026 ($MILLION)

FIGURE 27     SOUTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY PRODUCT CANCER TYPE, 2018–2026 ($MILLION)

FIGURE 28   SOUTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

FIGURE 29     SOUTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY DRUG TYPE, 2018–2026 ($MILLION)

FIGURE 30     SOUTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018–2026 ($MILLION)

FIGURE 31     EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , 2018–2026 ($MILLION)

FIGURE 32   EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY PRODUCT CANCER TYPE, 2018–2026 ($MILLION)

FIGURE 33     EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

FIGURE 34   EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY DRUG TYPE, 2018–2026 ($MILLION)

FIGURE 35    EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018–2026 ($MILLION)

FIGURE 36    ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , 2018–2026 ($MILLION)

FIGURE 37     ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY PRODUCT CANCER TYPE, 2018–2026 ($MILLION)

FIGURE 38    ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

FIGURE 39     ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY DRUG TYPE, 2018–2026 ($MILLION)

FIGURE 40     ASIA PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018–2026 ($MILLION

FIGURE 41    MIDDLE EAST AND AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET VALUE , 2018–2026 ($MILLION)

FIGURE 42     MIDDLE EAST AND AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY PRODUCT CANCER TYPE, 2018–2026 ($MILLION)

FIGURE 43     MIDDLE EAST AND AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)

FIGURE 44     MIDDLE EAST AND AFRICA CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET SHARE (%), BY DRUG TYPE, 2018–2026 ($MILLION)

FIGURE 45.    GLAXOSMITHKLINE PLC: FINANCIALS

FIGURE 46.    ABBVIE INC: FINANCIALS

FIGURE 47.    BIOGEN IDEC: FINANCIALS

FIGURE 48   PORTOLA PHARMACEUTICALS, INC: FINANCIALS

FIGURE 49.    GENENTECH INC: FINANCIALS

FIGURE 50.    MORPHOSYS AG: FINANCIALS

FIGURE 51.     F. HOFFMANN-LA ROCHE AG.: FINANCIALS

FIGURE 52.    TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS

FIGURE 53.    ASTRAZENECA.: FINANCIALS

FIGURE 54.    CELGENE CORPORATION: FINANCIALS

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report